Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Down 69.0% in June

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw a large drop in short interest in June. As of June 30th, there was short interest totaling 14,925 shares, a drop of 69.0% from the June 15th total of 48,137 shares. Based on an average trading volume of 628,782 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, Daiichi Sankyo presently has a consensus rating of “Hold”.

Daiichi Sankyo Trading Up 0.2%

DSNKY traded up $0.03 during trading on Friday, reaching $17.09. 98,573 shares of the company’s stock were exchanged, compared to its average volume of 265,043. The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18. Daiichi Sankyo has a one year low of $14.98 and a one year high of $27.50. The firm has a fifty day moving average price of $16.34 and a two-hundred day moving average price of $18.21. The stock has a market capitalization of $31.84 billion, a PE ratio of 18.18, a price-to-earnings-growth ratio of 2.94 and a beta of -0.17.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings results on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.18). The business had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, equities research analysts forecast that Daiichi Sankyo will post 0.98 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.